TNFRSF1B anticorps (FITC)

N° du produit ABIN2191751

Détail du produit anti-TNFRSF1B anticorps (FITC)

Antigène: TNFRSF1B (Tumor Necrosis Factor Receptor Superfamily, Member 1B (TNFRSF1B))

Reactivité: Souris

Hôte: Rat

Clonalité: Monoclonal

Conjugué: Cet anticorp TNFRSF1B est conjugé à/à la FITC

Application: Western Blotting (WB), Flow Cytometry (FACS), Immunoprecipitation (IP), Functional Studies (Func), Immunoassay (IA)

Stérilité: 0.2 μm filtered

Clone: HM102

Information d'application

Indications d'application: For immunohistochemistry, flow cytometry and Western blotting, dilutions to be used depend on detection system applied. It is recommended that users test the reagent and determine their own optimal dilutions. The typical starting working dilution is 1:50. For functional studies, in vitro dilutions have to be optimized in user's experimental setting. Positive RAW264.7 cells control

Restrictions: For Research Use only

Stockage

Buffer: PBS, containing 1 % bovine serum albumin.

Stock: 4 °C

Stockage commentaire: Product should be stored at 4 °C. Under recommended storage conditions, product is stable for at least one year. The exact expiry date is indicated on the label.

Références pour anticorps anti-TNFRSF1B (FITC) (ABIN2191751)

Brekke, Sagen, Bjerve: "Specificity of endogenous fatty acid release during tumor necrosis factor-induced apoptosis in WEHI 164 fibrosarcoma cells." dans: Journal of lipid research, Vol. 40, Issue 12, pp. 2223-33, (2000) (PubMed).

Tacchini-Cottier, Vesin, Redard, Buurman, Piguet: "Role of TNFR1 and TNFR2 in TNF-induced platelet consumption in mice." dans: Journal of immunology (Baltimore, Md. : 1950), Vol. 160, Issue 12, pp. 6182-6, (1998) (PubMed).

Détails sur TNFRSF1B

Antigène: TNFRSF1B (Tumor Necrosis Factor Receptor Superfamily, Member 1B (TNFRSF1B))

Autre désignation: Tnf-Rii (TNFRSF1B Produits)

Synonymes: anticorps CD120b, anticorps TBPII, anticorps TNF-R-II, anticorps TNF-R75, anticorps TNFBR, anticorps TNFR1B, anticorps TNFR2, anticorps TNFR80, anticorps p75, anticorps p75TNFR, anticorps TNF-RII/TNFRSF1B, anticorps TNFR-II, anticorps TNFRSF1B, anticorps TNF-R2, anticorps TNF-alphaR2, anticorps TNFRII, anticorps TNFalpha-R2, anticorps Tnfr-1, anticorps Tnfr2, anticorps rank, anticorps zgc:163064, anticorps TNF receptor superfamily member 1B, anticorps tumor necrosis factor receptor superfamily, member 1b, anticorps tumor necrosis factor receptor superfamily, member 1B, anticorps TNFRSF1B, anticorps Tnfrsf1b, anticorps tnfrsf1b

Sujet: The monoclonal antibody HM102 recognizes the extracellular part of membrane-bound TNF-RII as well as the soluble form of TNF-RII which is generated by proteolytic cleavage of the extracellular domain. The soluble form can still bind TNF-alpha with high affinity and functions as a TNF-alpha antagonist. TNF-alpha is an important signalling protein in the immune system which can activate inflammatory responses, induce apoptosis, regulate cellular proliferation, and may even promote cancer progression. TNF-alpha can bind to two structurally distinct membrane receptors, TNF-RI and TNFRII, which have both distinct and overlapping downstream signaling cascades. TNFRI is believed to be expressed on nearly all cell types, whereas TNFRII exhibits more restricted expression, being found on certain subpopulations of immune cells and several other cell types. A dominant role of TNFRII has been shown in thymocyte activation by TNF-alpha, whereas induction of cytotoxicity and other functions are mediated largely by TNF-RI. TNF-RI is equally well activated by both the 17 kDa soluble and 26 kDa membrane-bound form, whereas TNF-RII is activated only by the membrane bound form of TNF-alpha. The antibody is an agonistic receptor modulating antibody. It enhances in vitro TNF alpha responses by increasing the affinity of the soluble form of TNF-alpha for TNF-RII. Aliases Tumor necrosis factor receptor superfamily member 1B, CD120b, TNF-R2, p75, p80 TNF-alpha receptor

Pathways: Signalisation NF-kappaB, Apoptose, Cellular Response to Molecule of Bacterial Origin, Hepatitis C, Ubiquitin Proteasome Pathway